Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A. Bond, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood Advances|2021Cited by 41
Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab eraReem Karmali, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|American Journal of Hematology|2021Cited by 22
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous TransplantBrian T. Hill, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood|2019Cited by 17
Outcomes Following Early Relapse in Patients with Mantle Cell LymphomaDavid A. Bond, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood|2019Cited by 12
Treatment Outcomes and Prognostic Factors in 40 Patients with Primary Effusion LymphomaKrithika Shanmugasundaram, Kathryn Lurain, Mark N. Polizzotto et al.|Blood|2021Cited by 7